Source: European Medicines Agency (EU) Revision Year: 2021 Publisher: Recordati Rare Diseases, Immeuble Le Wilson, 70, Avenue du Général de Gaulle, 92800 Puteaux, France
Cystadrops 3.8 mg/mL eye drops solution.
Pharmaceutical Form |
---|
Eye drops solution. Viscous, clear solution. |
Each mL contains mercaptamine hydrochloride equivalent to 3.8 mg mercaptamine (cysteamine).
Excipient with known effect:
Each mL of eye drops solution contains 0.1 mg of benzalkonium chloride.
For the full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Mercaptamine |
Mercaptamine reduces corneal cystine crystal accumulation acting as a cystine-depleting agent by converting cystine to cysteine and cysteine-cysteamine mixed disulfides. |
List of Excipients |
---|
Benzalkonium chloride |
5 mL solution in a 10 mL amber glass vial closed by a bromobutyl stopper and sealed with an aluminium tear-off cap. A PVC dropper applicator with HDPE closure is packed separately and included in each carton box.
Each carton box contains 1 vial and 1 dropper applicator.
Pack of 1 carton box or multipack containing 4 carton boxes.
Not all pack sizes may be marketed.
Recordati Rare Diseases, Immeuble “Le Wilson”, 70, Avenue du Général de Gaulle, 92800 Puteaux, France
EU/1/15/1049/001
EU/1/15/1049/002
Date of first authorisation: 19 January 2017
Drug | Countries | |
---|---|---|
CYSTADROPS | Austria, Canada, Estonia, Finland, France, Croatia, Ireland, Israel, Lithuania, Netherlands, Poland, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.